Discontinuation of Oxytocin in the Second Stage of Labor and its Association with Postpartum Hemorrhage

Caitlin MacGregor; Beth Plunkett; Marci Adams; Richard Silver

doi:10.1055/a-1786-9096

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2024; 41(08): 1050-1054
DOI: 10.1055/a-1786-9096

Original Article

Discontinuation of Oxytocin in the Second Stage of Labor and its Association with Postpartum Hemorrhage

Caitlin MacGregor

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NorthShore University HealthSystem, University of Chicago Pritzker School of Medicine, Evanston, Illinois

,

Beth Plunkett

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NorthShore University HealthSystem, University of Chicago Pritzker School of Medicine, Evanston, Illinois

,

Marci Adams

²Department of Obstetrics and Gynecology, NorthShore University HealthSystem, University of Chicago Pritzker School of Medicine, Evanston, Illinois

,

Richard Silver

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NorthShore University HealthSystem, University of Chicago Pritzker School of Medicine, Evanston, Illinois

› Institutsangaben

Abstract

Objective The objective of the study was to evaluate whether patients with oxytocin discontinued during the second stage of labor (≥30 minutes prior to delivery) had a lower rate of postpartum hemorrhage (PPH) compared with those with oxytocin continued until delivery or discontinued <30 minutes prior to delivery.

Study Design Retrospective cohort study was performed from August 1, 2014 to July 31, 2019. Singleton pregnancies of 24 to 42 weeks gestation were included if they reached the second stage of labor and received oxytocin during labor. Patients on anticoagulants were excluded. Patients with oxytocin discontinued ≥30 minutes prior to delivery represented STOPPED and those with oxytocin continued until delivery or discontinued <30 minutes prior to delivery represented CONTINUED. Patient data were abstracted from the electronic medical record. The primary outcome was PPH (≥1,000 mL blood loss). Univariable analyses were performed to compare groups. Multi-variable logistic regression was performed to adjust for prespecified confounders. Planned sub-group analyses by the route of delivery were performed.

Results Of 10,421 total patients, 1,288 had oxytocin STOPPED and 9,133 had oxytocin CONTINUED. There were no significant differences in age, race, or ethnicity, body mass index, public insurance, gestational diabetes, or pregnancy-induced hypertension between STOPPED and CONTINUED. The PPH rate was 15.2 and 5.7% in STOPPED and CONTINUED, respectively (p < 0.001). After adjusting for confounders, STOPPED remained at higher odds for PPH (adjusted odds ratio 2.859, 95% confidence interval 2.394, 3.414, p < 0.001). Among cesarean deliveries only, there was no significant difference in the rate of PPH between STOPPED and CONTINUED (38.0 vs. 36.4%, respectively, p = 0.730). However, among vaginal deliveries, the rate of PPH was actually lower in STOPPED than CONTINUED (3.4 vs. 5.2%, respectively, p = 0.024).

Conclusion The rate of PPH was higher in patients with oxytocin STOPPED compared with CONTINUED. However, among vaginal deliveries, there was a significantly lower rate of PPH in STOPPED. These disparate findings may be explained by the variable impact of second-stage oxytocin on PPH as a function of delivery type.

Key Points

It is unclear if oxytocin use in the second stage of labor may independently increase the risk of hemorrhage.
Patients with oxytocin discontinued during the second stage of labor had a higher rate of PPH.
PPH was significantly lower among vaginal deliveries in patients with oxytocin discontinued.

Keywords

oxytocin - second stage of labor - postpartum hemorrhage - blood loss - vaginal delivery - cesarean delivery

Volltext

Referenzen

References
1 Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg 2010; 110 (05) 1368-1373
2 Say L, Chou D, Gemmill A. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014; 2 (06) e323-e333
3 Begley CM, Gyte GML, Devane D, McGuire W, Weeks A. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev 2015; 3 (03) CD007412
4 Westhoff G, Cotter AM, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev 2013; 2013 (10) CD001808
5 Merrill DC, Zlatnik FJ. Randomized, double-masked comparison of oxytocin dosage in induction and augmentation of labor. Obstet Gynecol 1999; 94 (03) 455-463
6 Crane JMG, Young DC. Meta-analysis of low-dose versus high-dose oxytocin for labour induction. J SOGC 1998; 20 (13) 1215-1223
7 Seitchik J, Amico J, Robinson AG, Castillo M. Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics. Am J Obstet Gynecol 1984; 150 (03) 225-228
8 Fraser W, Vendittelli F, Krauss I, Bréart G. Effects of early augmentation of labour with amniotomy and oxytocin in nulliparous women: a meta-analysis. Br J Obstet Gynaecol 1998; 105 (02) 189-194
9 Lavoie A, McCarthy RJ, Wong CA. The ED90 of prophylactic oxytocin infusion after delivery of the placenta during cesarean delivery in laboring compared with nonlaboring women: an up-down sequential allocation dose-response study. Anesth Analg 2015; 121 (01) 159-164
10 Foley A, Gunter A, Nunes KJ, Shahul S, Scavone BM. Patients undergoing cesarean delivery after exposure to oxytocin during labor require higher postpartum oxytocin doses. Anesth Analg 2018; 126 (03) 920-924
11 Boie S, Glavind J, Velu AV. et al. Discontinuation of intravenous oxytocin in the active phase of induced labour. Cochrane Database Syst Rev 2018; 8 (08) CD012274
12 Saccone G, Ciardulli A, Baxter JK. et al. Discontinuing oxytocin infusion in the active phase of labor: a systematic review and meta-analysis. Obstet Gynecol 2017; 130 (05) 1090-1096
13 Bor P, Ledertoug S, Boie S, Knoblauch NO, Stornes I. Continuation versus discontinuation of oxytocin infusion during the active phase of labour: a randomised controlled trial. BJOG 2016; 123 (01) 129-135
14 Ustunyurt E, Ugur M, Ustunyurt BO, Iskender TC, Ozkan O, Mollamahmutoglu L. Prospective randomized study of oxytocin discontinuation after the active stage of labor is established. J Obstet Gynaecol Res 2007; 33 (06) 799-803
15 Balki M, Ramachandran N, Lee S, Talati C. The recovery time of myometrial responsiveness after oxytocin-induced desensitization in human myometrium in vitro. Anesth Analg 2016; 122 (05) 1508-1515
16 Ananth CV, Schisterman EF. Confounding, causality, and confusion: the role of intermediate variables in interpreting observational studies in obstetrics. Am J Obstet Gynecol 2017; 217 (02) 167-175
17 Loudon JAZ, Groom KM, Hinkson L, Harrington D, Paterson-Brown S. Changing trends in operative delivery performed at full dilatation over a 10-year period. J Obstet Gynaecol 2010; 30 (04) 370-375
18 Unterscheider J, McMenamin M, Cullinane F. Rising rates of caesarean deliveries at full cervical dilatation: a concerning trend. Eur J Obstet Gynecol Reprod Biol 2011; 157 (02) 141-144
19 Davis G, Fleming T, Ford K, Mouawad MR, Ludlow J. Caesarean section at full cervical dilatation. Aust N Z J Obstet Gynaecol 2015; 55 (06) 565-571